Is it time to challenge the established theories surrounding type 1 diabetes?

被引:4
|
作者
Ludvigsson, Johnny [1 ]
机构
[1] Linkoping Univ, Dept Clin Expt Med, Div Pediat, SE-58185 Linkoping, Sweden
关键词
Aetiology; Autoimmunity; Pathogenesis; Type; 1; diabetes; 2; ANTI-CD3; MONOCLONAL-ANTIBODY; BETA-CELL FUNCTION; DOUBLE-BLIND; C-PEPTIDE; ONSET; MELLITUS; DIAGNOSIS; CHILDREN; RESPONSES; PANCREAS;
D O I
10.1111/apa.12452
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Type one diabetes (T1D) seems a well-defined disease, but its classification may be difficult. Evidence is weak that an autoimmune process with insulitis causes loss of the beta cells in all patients. Some scientists propose that it may be caused by a virus, increased hygiene or the early introduction of cow's milk or gluten, while views about the nerve supply, vascular function and the beta cells own role tend to be disregarded. Immune interventions have had limited success. There are differences, but also similarities, between T1D and type 2 diabetes (T2D). ConclusionSeveral views on T1D have become so widely accepted that they may actually hamper progress into the true cause of this disease. Research on T1D needs to be carried out with an open mind, and clinicians might be wise to recommend a lifestyle that aims to decrease both the risk of T1D and T2D.
引用
收藏
页码:120 / 123
页数:4
相关论文
共 50 条
  • [41] Immunological intervention to preserve beta-cell function in type 1 diabetes
    Schloot, N. C.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (18) : 915 - 921
  • [42] Preserved C-peptide is common and associated with higher time in range in Chinese type 1 diabetes
    Liu, Wei
    Fang, Yayu
    Cai, Xiaoling
    Zhu, Yu
    Zhang, Mingxia
    Han, Xueyao
    Li, Juan
    Yin, Sai
    Cai, Deheng
    Chen, Jing
    Wang, Lei
    Shi, Dawei
    Ji, Linong
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [43] Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes
    Buckner, Jane H.
    Nepom, Gerald T.
    JOURNAL OF AUTOIMMUNITY, 2016, 71 : 44 - 50
  • [44] A Cure for Type 1 Diabetes: Are We There Yet?
    Schaaf, Christopher
    Sussel, Lori
    DIABETES TECHNOLOGY & THERAPEUTICS, 2025,
  • [45] Immunotherapy of type 1 diabetes - How to rationally prioritize combination therapies in T1D
    Boettler, Tobias
    von Herrath, Matthias
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2010, 10 (12) : 1491 - 1495
  • [46] Prevention versus intervention of type 1 diabetes
    Brooks-Worrell, Barbara
    Palmer, Jerry P.
    CLINICAL IMMUNOLOGY, 2013, 149 (03) : 332 - 338
  • [47] Metabolic Abnormalities in the Pathogenesis of Type 1 Diabetes
    Zheng, Shuyao
    Mathews, Clayton E.
    CURRENT DIABETES REPORTS, 2015, 15 (09)
  • [48] The role of the physician-scientist in bridging basic and clinical research in type 1 diabetes
    Rigby, Mark R.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2010, 17 (02) : 131 - 142
  • [49] Temporal changes in the diagnosis of type 1 diabetes by diabetic ketoacidosis in Brazil: A nationwide survey
    Negrato, C. A.
    Cobas, R. A.
    Gomes, M. B.
    DIABETIC MEDICINE, 2012, 29 (09) : 1142 - 1147
  • [50] Persistent elevations in circulating INS DNA among subjects with longstanding type 1 diabetes
    Neyman, Anna
    Nelson, Jennifer
    Tersey, Sarah A.
    Mirmira, Raghavendra G.
    Evans-Molina, Carmella
    Sims, Emily K.
    DIABETES OBESITY & METABOLISM, 2019, 21 (01) : 95 - 102